Located in Osaka, Japan, Takeda is a research-based global company with its main focus on pharmaceuticals. As the largest pharmaceutical company in Japan and one of the global leaders of the industry, Takeda is committed to strive towards better health for people worldwide through leading innovation in medicine. Additional information about Takeda is available through its corporate website, http://www.takeda.com.
References
1) European Commission (Heidi wiki): Health in Europe. Available from:
https://webgate.ec.europa.eu/sanco/heidi...
. Accessed 12/11/12
2) Healy D et al. Mortality in schizophrenia and related psychoses: data from
two cohorts, 1875-1924 and 1994-2010. BMJ Open 2012;2:e001810
3) Tiihonen J et al. 11 year-follow up of mortality in patients with
schizophrenia: a population-based cohort study (FINN11 study). Lancet 2009;374:620-7
4) De Hert M et al. Nat Rev Endocrinol 2012;8:114-26
5) Balf G, et al. Prim Care Companion J Clin Psychiatry 2008;10:15-24
6) Hennekens CH et al. J Clin Psychiatry 2007 ; 28(Supp13) :4-7
7) Nakamura M et al. J Clin Psychiatry 2009;70:829-36
8) Nasrallah H et al. J Psychiatric Research 2013;47(5):670-7
9) Meltzer H et al. Am J Psychiatry 2011;168:957-67
10) Loebel A et al. Schizophr Res 2013;145(1-3):101-9
11) Ogasa M et al. Psychopharmacol [Berl] 2013;225(3):519-30
12) Citrome L et al. Int Clin Psychopharmacol 2012;27:165-76
13) Company Core Data Sheet/ Swiss SmPC, June 2013
14) Kane J. J Clin Psychiatry 2011;72(Suppl 1):24-28
15) Pikalov A et al. Eur Neuropsychopharmacol 2012;22(Suppl 2):S340
16) Citrome L. Adv Ther 2012;29:815-25
17) McEvoy J et al. J Clin Psychiatry 2013;74(2):170-9
18) Loebel A et al. Schizophr Res 2013; 147: 95-102
19) Stahl et al J Clin Psychiatry 2013
20) Chang C-K et al. Life Expectancy at Birth for People with Serious Mental
Illness and Other Major Disorders from a Secondary Mental Health Care Case Register in
London. PLoS One 2011;6:e19590
21) Laursen TM. Life expectancy among persons with schizophrenia or bipolar
affective disorder. Schizophr Res 2011;131:101-4
22) Lewis DA and Lieberman JA. Neuron 2000;28:325-34
23) Faries DE et al. Clinical and economic ramifications of switching
antipsychotics in the treatment of schizophrenia. BMC Psych 2009;9:54
24) Tsutsumi C et al. The evolution of antipsychotic switch and polypharmacy in
natural practice - A longitudinal perspective. Schizophr Res 2011;130:40-6
25) Salize HJ et al. Cost of schizophrenia in six European countries. Schizophr
Res 2009;111(1-3):70-7
26) Mangalore R and Knapp R. Cost of schizophrenia in England. J Ment Health
Policy Econ 2007;10(1):23-41
27) Zeidler J et al. The costs of schizophrenia and predictors of
hospitalisation from the statutory health insurance perspective. Health Econ Rev
2012;2(1):9
CONTACT: Media Contacts: Sunovion Europe Media Contacts, Suzanne Walsh,Phone: +44-2083928051, swalsh@rdcomms.com; Claire Grindal, Phone:+44-7887-643964, cgrindal@rdcomms.com; Takeda Media Contacts: ElissaJohnsen, Takeda Pharmaceuticals International GmbH, Phone: +1-224-554-3185,elissa.johnsen@takeda.com; Media Contacts in Japan: Dainippon SumitomoPharma Co., Ltd., Corporate Communications Dept., Phone: +81-6-6203-1407(Osaka), +81-3-5159-3300 (Tokyo), Takeda Pharmaceutical Company Limited,Corporate Communications Dept. (PR/IR), Phone: +81-3-3278-2037
